Pfizer announced Monday morning that late-stage clinical trial data show that its vaccine candidate is over 90 percent effective in preventing COVID-19.
The announcement was widely greeted as a sorely needed positive development in the fight against the virus, which is raging across the country.
The drugmaker said it conducted an analysis of 94 confirmed cases in trial participants after enrolling 43,538 participants in a larger study. The company added that it hopes to have the amount of safety data required for a Food and Drug Administration (FDA) emergency use authorization by the third week of November.
The vaccine requires two doses, and protection was achieved 28 days after the first dose, Pfizer said.
Read more at The Hill.